RadNet has completed the acquisition of breast AI developer iCAD, which will be integrated into RadNet's subsidiary DeepHealth.
Through the acquisition, iCAD's AI portfolio for breast cancer detection, risk evaluation, breast density, and breast arterial calcification assessment will be integrated with DeepHealth’s screening and diagnostic software.
RadNet estimates that with iCAD's installed base of more than 1,500 healthcare provider locations worldwide, this acquisition will allow DeepHealth to scale its work to over 10 million mammograms annually.
